Portugal's single national cancer registry, created by Law 53/2017 and working since 1 January 2018. Every public, social and private health service must record each new cancer within nine months of learning of the diagnosis. It counted 57,878 new cancers in 2019, and its coordinator reported 60,954 for 2022.
Law 53/2017 of 14 July 2017, in force from 1 January 2018, creates the Registo Oncológico Nacional as a centralised registry on a single electronic platform, to collect and analyse data on every cancer patient diagnosed or treated in mainland Portugal and the autonomous regions. Its stated purposes are monitoring the activity of institutions, the effectiveness of organised screening and of treatment, epidemiological surveillance and research, and, with the medicines authority INFARMED, monitoring the effectiveness of medicines and medical devices. Every public, social and private health service must register each new cancer within nine months of learning of the diagnosis and update the stage, treatments and vital status at least once a year. The data of the former regional registries, of the Portuguese paediatric cancer registry and of the autonomous regions' registries are integrated into it. The board of the Francisco Gentil Portuguese Oncology Institute group administers it and names a coordinator from one of the three oncology institutes for three years, rotating between them.
Its 2019 report, edited and published by IPO Porto, counts 57,878 new cancers in people resident in Portugal diagnosed in 2019 and registered by 9 September 2022, a crude rate of 562.1 per 100,000, of which 31,507 were in men and 26,371 in women; breast (8,567), prostate (6,912) and colon (5,483) were the commonest sites. The report counts all invasive cancers except basal cell skin cancer, plus in situ and uncertain-behaviour bladder tumours and, in children under 15, benign brain tumours. Its coordinator, Maria José Bento, reported 60,954 new cancers for 2022 (579.6 per 100,000) in a note sent to the press in December 2025. The OECD and European Commission's 2025 profile says the registry has integrated the regional, paediatric and island registries and published incidence and mortality, but that survival and stage at diagnosis remain unpublished.
Shares Instituto Português de Oncologia de Coimbra Francisco Gentil, Instituto Português de Oncologia de Lisboa Francisco Gentil.
Shares Instituto Português de Oncologia de Lisboa Francisco Gentil, Instituto Português de Oncologia do Porto Francisco Gentil.
Shares Instituto Português de Oncologia do Porto Francisco Gentil, Breast cancer (all types), Prostate cancer.
Shares Instituto Português de Oncologia de Lisboa Francisco Gentil, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/